Suppr超能文献

一例推测与新冠病毒疫苗相关的膜性肾病病例。

A Case of Membranous Nephropathy Hypothesized to be Associated With COVID-19 Vaccine.

作者信息

Rashid Wahida, Mousa Heba, Khan Jahanzeb, Ijaz Fakhar, Ezell Gerry D

机构信息

Internal Medicine, Baptist Health - University of Arkansas for Medical Sciences, North Little Rock, USA.

Nephrology, Baptist Health North Little Rock, North Little Rock, USA.

出版信息

Cureus. 2022 Apr 18;14(4):e24245. doi: 10.7759/cureus.24245. eCollection 2022 Apr.

Abstract

A 56-year-old male patient with a medical history of essential hypertension was referred to the emergency room after he was found to have a serum creatinine level of 13 mg/dL at his primary care physician's office. The patient reported that he had developed a coronavirus disease 2019 (COVID-19)-like infection six months prior that was not confirmed. Two months later, he started to notice dyspnea on exertion and bilateral lower limb swelling and was started on furosemide. He received the first dose of the Moderna COVID-19 vaccine a month before the presentation but did not receive the second dose. Subsequently, his lower limb swelling and exertional dyspnea started worsening. He denied any new medication, dysuria, oliguria, hematuria, fever, or any other symptoms. Initial evaluation was consistent with kidney failure. Hypocalcemia and hyperphosphatemia were noted, along with medical renal disease on renal ultrasound. Eosinophils and nephrotic-range proteinuria were found in the urine. His serum phospholipase A2 receptor (PLA2R) antibodies were positive. A renal biopsy showed membranous glomerulonephritis with moderate segmental sclerosis, as well as tubulointerstitial fibrosis with neutrophils, consistent with acute interstitial nephritis. Positive staining for PLA2R in the glomerular deposits suggested primary membranous nephropathy (MN). He was treated with prednisone first, and when the kidney biopsy was conclusive for membranous glomerulopathy, he was started on rituximab. On admission, he received hemodialysis intermittently, but this was stopped a month after discharge as his renal function normalized. Recently, there have been numerous cases reported with new onset of glomerular disease after receiving the COVID-19 vaccine. Further studies of vaccinated patients are needed to determine whether the severe acute respiratory syndrome coronavirus 2 virus vaccination is associated with a higher risk of MN and to identify potential predisposing factors and mechanisms of kidney injury in patients in whom it occurs.

摘要

一名56岁男性患者,有原发性高血压病史,在其初级保健医生办公室检查发现血清肌酐水平为13mg/dL后被转诊至急诊室。患者报告称,6个月前曾出现类似2019冠状病毒病(COVID-19)的感染,但未得到确诊。两个月后,他开始出现劳力性呼吸困难和双侧下肢肿胀,并开始服用呋塞米。在就诊前一个月,他接种了第一剂Moderna COVID-19疫苗,但未接种第二剂。随后,他的下肢肿胀和劳力性呼吸困难开始加重。他否认服用任何新药、排尿困难、少尿、血尿、发热或任何其他症状。初步评估结果与肾衰竭一致。发现有低钙血症和高磷血症,肾脏超声显示为医学性肾病。尿液中发现嗜酸性粒细胞和肾病范围的蛋白尿。他的血清磷脂酶A2受体(PLA2R)抗体呈阳性。肾活检显示为膜性肾小球肾炎伴中度节段性硬化,以及伴有中性粒细胞的肾小管间质纤维化,符合急性间质性肾炎。肾小球沉积物中PLA2R阳性染色提示原发性膜性肾病(MN)。他首先接受了泼尼松治疗,当肾活检确诊为膜性肾小球病时,开始使用利妥昔单抗治疗。入院时,他间歇性接受血液透析,但出院一个月后,随着肾功能恢复正常,透析停止。最近,有大量关于接种COVID-19疫苗后新发肾小球疾病的病例报告。需要对接种疫苗的患者进行进一步研究,以确定严重急性呼吸综合征冠状病毒2病毒疫苗接种是否与MN的较高风险相关,并确定发生MN的患者中潜在的易感因素和肾损伤机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5bd/9116517/aeb190fcd7ab/cureus-0014-00000024245-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验